Cointime update: AstraZeneca announced at the ninth China International Import Expo that it has established AstraZeneca Cell Technology (Shanghai) Co., Ltd. in Shanghai’s Lingang area, completing its end-to-end cell therapy footprint in China from R&D to commercial manufacturing and supporting supply to Chinese and Asian markets. The company also began construction on an upgrade to a new drug development and supply building at its Wuxi manufacturing and supply base, investing nearly RMB 200 million to boost production and global supply of innovative cardiovascular medicines.
AstraZeneca Opens Cell Therapy Unit in Shanghai, Expands Wuxi Site
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
6m ago
S&P 500 Falls 2.0% to 7,498.13
6m ago
Nasdaq falls 3.3% as AI stocks sell off on Democratic midterm sweep
7m ago
US memory chip stocks extend selloff; SanDisk plunges over 17%
8m ago
Fed’s Barkin: Rate Hikes Can Affect Demand and Ultimately Oil Prices
10m ago
VIX Spikes 40% to 23.29
36m ago
Nvidia Falls 5.6%, Hitting Intraday Low Since April